Endocrine Abstracts

Background: Systematic exploration for anterior pituitary deficiency in patients harboring pituitary microadenomas is not well defined. So far, little is known on the involvement of pituitary function in clinically non-functioning pituitary microadenomas (CNFPM).Objective: To evaluate the prevalence of anterior pituitary insufficiency, defined as at least one hormonal deficiency, in patients diagnosed of CNFPM.Patients and methods:...

Objetive: To assess the clinical features of incidental clinically non-functioning pituitary adenoma (NFPA) and to analyze its natural history.Methods: A multicenter retrospective study in patients with NFPA followed-up from 1992 to 2015 was performed.Results: Fifty-seven patients were studied (29 women (50.9%); age 55.8±16.7 years. 43.9% were older than 60 years, 40.3% belonged to the age group of 40–60 years and 15.8% w...

Objective: To assess clinical outcome after pituitary surgery in patients nonfunctioning pituitary adenomas (NFPA) surgically treated in the past 3 decades in three tertiary referral hospitals.Methods: A multicenter retrospective study on clinical and pathological characteristics, treatment patterns, and outcome in patients with NFPA periodically followed up in specialized neuroendocrinology units who underwent surgery in the period 1982–2015 was pe...

Objective: The aim of our study was to investigate the characteristics of the acromegalic patients followed at a tertiary Universitary Hospital and to evaluate the results of the recommended treatment protocols.Patients and methods: All our acromegalic patients were included (n=48; 27 women). Demographic, hormonal, visual and imaging data at diagnosis and during follow-up, as well as treatments applied, were recorded.Results...

Introduction: Although involved in feeding and weight homeostasis, stimulation of pituitary GH secretion is the best established action of stomach-produced hormone ghrelin. However, its role in regulation of GH secretion is not yet clear. Some evidence indicates that circulating concentrations of GH and/or IGF-I could influence ghrelin levels. The pathophysiology of ghrelin secretion in acromegaly (specially aftar an oral glucose tolerance test (OGTT) is unclear.<p class="...

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...